Adage Capital Partners Gp, L.L.C. Akero Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $19 Million - $84 Million	-1,668,009 Reduced 85.85%	275,000 $6.42 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $45.6 Million - $57.8 Million	-1,105,868 Reduced 36.27%	1,943,009 $98.3 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $24.3 Million - $37.5 Million	658,986 Added 27.57%	3,048,877 $142 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $39.7 Million - $53.5 Million	1,064,914 Added 80.37%	2,389,891 $91.4 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $15.1 Million - $24.8 Million	452,477 Added 51.86%	1,324,977 $72.6 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $8.86 Million - $29.7 Million	872,500 New	872,500 $29.7 Million
Q1 2020 May 15, 2020	SELL	$12.8 - $27.05 $6.91 Million - $14.6 Million	-540,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.37 - $27.27 $260,550 - $409,050	15,000 Added 2.86%	540,000 $12 Million
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $7.23 Million - $12.8 Million	428,279 Added 442.8%	525,000 $11.9 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $1.75 Million - $1.92 Million	96,721 New	96,721 $1.85 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.42B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.